293 related articles for article (PubMed ID: 12239173)
21. C/EBPbeta: a major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells.
Duprez E; Wagner K; Koch H; Tenen DG
EMBO J; 2003 Nov; 22(21):5806-16. PubMed ID: 14592978
[TBL] [Abstract][Full Text] [Related]
22. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
[TBL] [Abstract][Full Text] [Related]
23. NLS-RARα Inhibits the Effects of All-trans Retinoic Acid on NB4 Cells by Interacting with P38α MAPK.
Xiao C; Zhong L; Shan Z; Xu T; Gan L; Song H; Yang R; Li L; Liu B
Int J Med Sci; 2016; 13(8):611-9. PubMed ID: 27499693
[TBL] [Abstract][Full Text] [Related]
24. Differential gene expression in retinoic acid-induced differentiation of acute promyelocytic leukemia cells, NB4 and HL-60 cells.
Lee KH; Chang MY; Ahn JI; Yu DH; Jung SS; Choi JH; Noh YH; Lee YS; Ahn MJ
Biochem Biophys Res Commun; 2002 Sep; 296(5):1125-33. PubMed ID: 12207890
[TBL] [Abstract][Full Text] [Related]
25. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein.
Nervi C; Ferrara FF; Fanelli M; Rippo MR; Tomassini B; Ferrucci PF; Ruthardt M; Gelmetti V; Gambacorti-Passerini C; Diverio D; Grignani F; Pelicci PG; Testi R
Blood; 1998 Oct; 92(7):2244-51. PubMed ID: 9746761
[TBL] [Abstract][Full Text] [Related]
26. PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter.
Tabe Y; Konopleva M; Kondo Y; Contractor R; Jin L; Ruvolo V; Tsutsumi-Ishii Y; Miyake K; Miyake N; Ohsaka A; Nagaoka I; Issa JP; Andreeff M
Ann Hematol; 2006 Oct; 85(10):689-704. PubMed ID: 16832676
[TBL] [Abstract][Full Text] [Related]
27. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
Lo-Coco F; Hasan SK
Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
[TBL] [Abstract][Full Text] [Related]
28. PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APL.
Tabe Y; Konopleva M; Kondo Y; Contractor R; Tsao T; Konoplev S; Shi Y; Ling X; Watt JC; Tsutsumi-Ishii Y; Ohsaka A; Nagaoka I; Issa JP; Kogan SC; Andreeff M
Cancer Biol Ther; 2007 Dec; 6(12):1967-77. PubMed ID: 18075297
[TBL] [Abstract][Full Text] [Related]
29. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
Jing Y
Leuk Lymphoma; 2004 Apr; 45(4):639-48. PubMed ID: 15160934
[TBL] [Abstract][Full Text] [Related]
30. Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia.
Jing Y; Xia L; Waxman S
Blood; 2002 Aug; 100(3):1008-13. PubMed ID: 12130515
[TBL] [Abstract][Full Text] [Related]
31. Expression of the Zn finger gene, EVI-1, in acute promyelocytic leukemia.
Xi ZF; Russell M; Woodward S; Thompson F; Wagner L; Taetle R
Leukemia; 1997 Feb; 11(2):212-20. PubMed ID: 9009083
[TBL] [Abstract][Full Text] [Related]
32. All-trans retinoic acid (ATRA)-induced TFEB expression is required for myeloid differentiation in acute promyelocytic leukemia (APL).
Orfali N; O'Donovan TR; Cahill MR; Benjamin D; Nanus DM; McKenna SL; Gudas LJ; Mongan NP
Eur J Haematol; 2020 Mar; 104(3):236-250. PubMed ID: 31811682
[TBL] [Abstract][Full Text] [Related]
33. Transcription therapy for acute promyelocytic leukaemia.
Douer D
Expert Opin Investig Drugs; 2000 Feb; 9(2):329-46. PubMed ID: 11060680
[TBL] [Abstract][Full Text] [Related]
34. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
Zheng X; Seshire A; Rüster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M
Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181
[TBL] [Abstract][Full Text] [Related]
35. PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.
Bräuer-Hartmann D; Hartmann JU; Wurm AA; Gerloff D; Katzerke C; Verga Falzacappa MV; Pelicci PG; Müller-Tidow C; Tenen DG; Niederwieser D; Behre G
Cancer Res; 2015 Aug; 75(16):3411-24. PubMed ID: 26041820
[TBL] [Abstract][Full Text] [Related]
36. PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia.
Ohnishi K
Int J Clin Oncol; 2007 Oct; 12(5):313-7. PubMed ID: 17929112
[TBL] [Abstract][Full Text] [Related]
37. UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia.
Kitareewan S; Pitha-Rowe I; Sekula D; Lowrey CH; Nemeth MJ; Golub TR; Freemantle SJ; Dmitrovsky E
Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3806-11. PubMed ID: 11891284
[TBL] [Abstract][Full Text] [Related]
38. Restoration of CCAAT enhancer binding protein α P42 induces myeloid differentiation and overcomes all-trans retinoic acid resistance in human acute promyelocytic leukemia NB4-R1 cells.
Wang L; Xiao H; Zhang X; Liao W; Fu S; Huang H
Int J Oncol; 2015 Nov; 47(5):1685-95. PubMed ID: 26397153
[TBL] [Abstract][Full Text] [Related]
39. Selenite promotes all-trans retinoic acid-induced maturation of acute promyelocytic leukemia cells.
Misra S; Selvam AK; Wallenberg M; Ambati A; Matolcsy A; Magalhaes I; Lauter G; Björnstedt M
Oncotarget; 2016 Nov; 7(46):74686-74700. PubMed ID: 27732960
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia.
Tomita A; Kiyoi H; Naoe T
Int J Hematol; 2013 Jun; 97(6):717-25. PubMed ID: 23670176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
